New Zealand's blood cancer landscape faces significant challenges, as revealed by the newly released State of Blood Cancer in New Zealand report from Blood Cancer NZ. This landmark document, the first of its kind, paints a detailed picture of a system struggling to keep pace with global advances in haematological care. With around 3,000 new diagnoses annually and approximately 27,000 people living with the disease, blood cancers represent the third leading cause of cancer death in the country and the fastest-growing contributor to cancer mortality over the past decade.

Blood cancers, also known as haematological malignancies, encompass over 100 subtypes including leukaemia (cancer of the blood-forming tissues), lymphoma (cancers of the lymphatic system), myeloma (a plasma cell cancer affecting bones and blood), myelodysplastic syndromes (MDS, where bone marrow fails to produce healthy cells), and myeloproliferative neoplasms (MPN, overproduction of blood cells). Unlike solid tumours, these conditions lack preventive measures or routine screening, relying heavily on medicines—chemotherapy, targeted therapies, immunotherapies, and cellular treatments—as the primary intervention. Survival has improved internationally due to precision medicine, but New Zealand's outcomes lag, with five-year net survival rates for leukaemia at 57.7% compared to Australia's 66.4%, Hodgkin lymphoma at 80.2% versus 88.6%, non-Hodgkin lymphoma (NHL) at 68.4% versus 77.4%, and myeloma at 58.9% versus 60.7%.

🩸 The Growing Burden and Disparities

The lifetime risk stands at 1 in 18, higher than for melanoma or lung cancer, with annual deaths rising nearly 40% since 2008 despite no age-standardised mortality improvement over 15 years. Māori and Pacific peoples face higher incidence rates, slower income recovery post-diagnosis, and persistent inequities. Deprived communities (NZDep quintile 5) experience 40.4% income drops after diagnosis, exacerbating financial toxicity where 45% of patients report significant out-of-pocket costs and 69% dip into savings. Myeloma patients are hit hardest, with unfunded treatments often exceeding $100,000 per year.

Hospital costs reached $209 million in 2023, predominantly inpatient ($149.6 million), with $56.3 million in social benefits for over 14,000 beneficiaries. Leukaemia incurs the highest per-patient expense at $45,610. These figures underscore a system under strain, where fragmented planning across agencies leads to inconsistent investment and suboptimal care delivery.

Treatment Access: A Clear International Lag

New Zealand trails comparable nations like Australia, the UK, and Canada by up to 20 years in funding modern therapies. Australia funds 24 blood cancer medicines (42 medicine-indication pairs) unavailable here, including 12 with substantial clinical benefit per European Society for Medical Oncology (ESMO) guidelines. Patients exhaust funded options faster, facing relapse without curative alternatives like CAR-T cell therapy, available routinely overseas but trial-only in NZ, often requiring international travel.

Stem cell transplants face delays beyond the recommended 6-12 weeks, risking progression. Specific gaps include:

• Acute Myeloid Leukaemia (AML): Gilteritinib, oral azacitidine, CPX-351, decitabine + cedazuridine.
• Chronic Lymphocytic Leukaemia (CLL): Acalabrutinib, idelalisib.
• Non-Hodgkin Lymphoma: Polatuzumab vedotin, axicabtagene ciloleucel (CAR-T).
• Myeloma: Daratumumab, carfilzomib, selinexor, elranatamab.
• Others: Blinatumomab (ALL), momelotinib (MPN), ruxolitinib (graft-versus-host disease).

Pharmac's fixed budget contrasts with OECD averages (0.4% vs 1.4% GDP on medicines), delaying approvals and leaving patients self-funding or migrating for care. For more on international comparisons, explore the full report.

System Challenges: Workforce and Diagnostics

Haematology specialists are scarce, with 70% expressing dissatisfaction amid rising caseloads. Multi-disciplinary teams (MDTs) lack consistent staffing, and recruitment falters due to burnout and limited training pathways. Diagnostic delays persist—only 86% meet the four-month Faster Cancer Treatment (FCT) target—with fragmented lab governance (75% commercial) causing variable turnaround times and uneven genomic testing. No national quality framework exacerbates inequities.

Clinical trial participation is low at 14% lifetime, hampered by no reimbursement, geographic barriers, and declining registrations. This cycle—limited therapies, workforce pressure, suboptimal outcomes—increases relapse rates and service demand.

University Research: Leading the Charge at Home

New Zealand universities play a pivotal role in bridging these gaps. The Blood Cancer Research Unit (LBCRU) at the University of Auckland, partnered with Blood Cancer NZ since 2013, pioneers personalised medicine using mouse and zebrafish models. Achievements include a myeloid gene panel for all AML patients in Auckland, expanding nationwide, enhancing diagnostics and targeted therapies.

University of Otago's cancer research examines trends in incidence, mortality, and Māori disparities, revealing higher blood cancer burdens and lower survivals for non-Hodgkin lymphoma (64% Māori vs 68% European). Recent studies link deprivation to poorer outcomes, informing policy. Medical schools at Auckland, Otago, and others train future haematologists, yet shortages persist, highlighting needs for expanded postgraduate programs and research funding.

Strengthening university-led trials and MDT training could accelerate access to innovations like CAR-T, developed locally at Malaghan Institute.

Government Response and Recent Advances

In response to the report, launched April 21, 2026, at Parliament by Health Minister Simeon Brown, the government established a Blood Cancer Oversight Group for coordination. Pharmac recently funded venetoclax combinations for CLL from May 1, 2026, widening ibrutinib access—a step forward but insufficient for broader gaps. For context on Pharmac decisions, see RNZ's coverage here.

Five Priority Recommendations

The report outlines actionable steps:

1. National Taskforce: Lead coordination, accountability, annual reporting.
2. Treatment Access: Align with best practice; reform medicine funding for timely approvals.
3. Pathways: Embed national guidelines; fund consistent diagnostics/treatment.
4. Research/Trials: Reimburse participation; develop national roadmap.
5. Workforce/Capacity: Expand specialists, infrastructure; $27M for transplants.

Milestones target no needless deaths by 2035, with personalised therapies routine.

Implications for Māori and Equity

Māori bear disproportionate burdens, with university studies like Otago's emphasising culturally responsive care. Diagnostic delays and unfunded therapies compound inequities, but initiatives like precision health strategies could address this through university genomics research.

Future Outlook: Innovation and Hope

Optimism stems from local innovations—LBCRU's gene panels, Malaghan's CAR-T—and global trends like bispecific antibodies. Universities must ramp up trials, training, and collaborations. With oversight and funding uplifts ($604M to Pharmac proposed), NZ could match peers, improving survivals and quality of life.

For those in higher education, opportunities abound in haematology research jobs and medical training. Explore research positions or higher ed careers to contribute.

Photo by Bermix Studio on Unsplash

The report signals a turning point. By prioritising university research, workforce development, and equitable access, New Zealand can transform blood cancer outcomes. Patients, clinicians, and academics united offer real hope.